Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions

Eli Lilly shares fell about 2% after weekly prescription data showed mixed GLP-1 trends: Mounjaro prescriptions rose to 758,400 total and 367,900 new, while Zepbound slipped to 615,300 total despite higher new starts of 350,600. Across the broader GLP-1 portfolio, total prescriptions edged down 0.3% week over week to 1.503M, even as Lilly held roughly 59% share of new GLP-1 prescriptions and the category grew 32% year over year. Foundayo recorded about 3,700 prescriptions in its second week, and Morgan Stanley said it sees about 6% upside to 2026 Mounjaro/Zepbound estimates.

Analysis

The market is reacting to a sequencing issue, not a demand collapse. A modest weekly dip in the mature GLP-1 franchise is being masked by the more important signal: Lilly is still converting share of new prescriptions at an unusually high level, which matters more for 6-12 month revenue than one week of total scripts. That makes the selloff look like a positioning unwind in a crowded winner rather than a fundamental break in the obesity/diabetes thesis.

The second-order read is that Lilly’s launch engine is starting to broaden the demand pool faster than competitors can respond, even if each individual product’s early cadence looks uneven. Foundationally, the market is still expanding at a very rapid clip, so near-term weekly softness in legacy products is more likely mix/normalization than share loss. The real competitive pressure falls on peers without comparable scale in manufacturing, physician access, and payer leverage; their issue is not just losing share, but being forced to compete into a category where Lilly controls the most attractive incremental patient flow.

The setup also creates a tactical opportunity around expectations. Morgan Stanley’s positive estimate revision language suggests sell-side models are still catching up, which means near-term volatility can stay elevated as traders anchor on weekly data rather than forward run-rate. The risk case is that if the next 2-4 weeks show sequential stagnation in total scripts while new starts remain flat, the market may de-rate the growth narrative before the launch contribution becomes visible in quarterly numbers.

The contrarian view is that the current dip may be underestimating the value of share-of-new-prescriptions versus absolute weekly totals. In obesity/diabetes, new starts are the leading indicator; total scripts lag and can look noisy because refill dynamics are affected by adherence, titration, and supply normalization. If that holds, this is more likely a buy-the-dip-on-data-noise event than the start of a meaningful top in the franchise.

Key Decisions for Investors

• Buy LLY on 1-3 day weakness only if it holds above the prior weekly support band; target a 4-8 week rebound as the market refocuses on share-of-new-prescriptions rather than noisy total scripts. Risk/reward: modest downside if the next print disappoints, but asymmetric upside if the launch remains on plan.
• Pair trade: long LLY / short a basket of GLP-1 laggards (e.g., NVO or a healthcare ETF underweight LLY) over 1-2 months. Thesis: Lilly’s share-of-new starts should continue to compound while rivals face slower conversion and weaker launch momentum.
• Sell near-dated put spreads in LLY with 4-6 week tenor, struck below the post-news reaction low. This monetizes elevated event-driven volatility while expressing the view that the move is overdone relative to the underlying demand trend.
• If looking for a cleaner catalyst trade, initiate a tactical long in IQV over 2-6 weeks. Weekly prescription data staying highly relevant should support continued demand for real-world analytics and market-intelligence services, even if the healthcare beta remains mixed.